Grace Y. T. Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Grace Y. T. Tan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Wendy W. Hwang-Verslues
Genomics Research Center, Academia Sinica, Taipei, Taiwan
11 shared publications - Chen-Hsin Albert Yu
Institute of Molecular Biology, Academia Sinica
10 shared publications - Li-Tzu Cheng
Genomics Research Center, Academia Sinica, Taipei, Taiwan
10 shared publications - Cheng-Kai Wang
Genomics Research Center, Academia Sinica, Taipei, Taiwan
9 shared publications - Fang-Pei Chang
Genomics Research Center, Academia Sinica, Taipei, Taiwan
9 shared publications - Samyuktha Sridharan
Genomics Research Center, Academia Sinica, Taipei, Taiwan
9 shared publications
Latest Publications
- Open Access
- 3 April 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (5) , 1933-1966
BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC)
Ovarian clear cell carcinomas (OCCC), particularly cases that retain wild-type AT-rich interactive domain 1 A (ARID1A) expression (approximately 50% of the OCCC cases), are chemoresistant and lack specific therapies. We identified BMAL2 as a critical OCCC oncogene that promotes tumorigenesis by preventing endogenous DNA damage. BMAL2 depletion altered the expression of genes encoding DNA damage repair proteins, including RAD51, a core enzyme of the homologous recombination (HR) pathway. This led to DNA double-stranded break accumulation, decreased cell viability and reduced tumor growth. This dependence on BMAL2 to maintain DNA integrity and cell viability can be a new route to suppress OCCC. Consistent with this idea, we found that GW833972A, a cannabinoid receptor agonist, bound BMAL2 with high affinity and facilitated its protein degradation. This in turn reduced RAD51 expression, leading to an accumulation of DNA damage, decreased cell viability and reduced OCCC tumor growth. GW833972A is effective by itself at high dose and can also be used at lower dosages to enhance the effectiveness of Poly (ADP-ribose) polymerase inhibitor (PARPi) treatments in BMAL2-expressing OCCC. Together, our findings reveal an essential oncogenic role of BMAL2 and demonstrate that it is an appealing therapeutic target, especially for ARID1A-wt OCCC.
- 3 April 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (5) , 1933-1966
Open AccessBMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC)
Ovarian clear cell carcinomas (OCCC), particularly cases that retain wild-type AT-rich interactive domain 1 A (ARID1A) expression (approximately 50% of the OCCC cases), are chemoresistant and lack specific therapies. We identified BMAL2 as a critical OCCC oncogene that promotes tumorigenesis by preventing endogenous DNA damage. BMAL2 depletion altered the expression of genes encoding DNA damage repair proteins, including RAD51, a core enzyme of the homologous recombination (HR) pathway. This led to DNA double-stranded break accumulation, decreased cell viability and reduced tumor growth. This dependence on BMAL2 to maintain DNA integrity and cell viability can be a new route to suppress OCCC. Consistent with this idea, we found that GW833972A, a cannabinoid receptor agonist, bound BMAL2 with high affinity and facilitated its protein degradation. This in turn reduced RAD51 expression, leading to an accumulation of DNA damage, decreased cell viability and reduced OCCC tumor growth. GW833972A is effective by itself at high dose and can also be used at lower dosages to enhance the effectiveness of Poly (ADP-ribose) polymerase inhibitor (PARPi) treatments in BMAL2-expressing OCCC. Together, our findings reveal an essential oncogenic role of BMAL2 and demonstrate that it is an appealing therapeutic target, especially for ARID1A-wt OCCC.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- Open Access
BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)
Ovarian clear cell carcinoma (OCCC) is highly chemo-resistant and has worse clinical outcome at advanced stages than other ovarian cancer subtypes. The most frequent (∼50%) alterations in OCCC are AT-rich interactive domain 1A gene (ARID1A) mutations which lead to ARID1A deficiency. However, OCCC that retains ARID1A function differs substantially from ARID1A mutated OCCC. Particularly, targeted therapies that sensitize ARID1A-deficient OCCC to DNA damage are largely ineffective against OCCC with wild-type (wt) ARID1A. Thus, it is important to identify druggable targets and develop targeted therapies specifically for ARID1A-wt OCCC. We identified BMAL2 as a critical OCCC oncogene that promotes tumorigenesis by preventing DNA damage from endogenous origins. BMAL2 depletion altered expression of genes in DNA damage repair pathways, including RAD51, a core enzyme of the homologous recombination (HR) pathway. This led to double-stranded break accumulation, decreased cell viability and reduced tumor growth. This dependence on BMAL2 to maintain DNA integrity and cell viability can be a new route to suppress ARID1A-wt OCCC. Consistent with this idea, we found that GW833972A, a cannabinoid receptor agonist, bound BMAL2 with high affinity and facilitated its degradation. This in turn reduced RAD51 expression, leading to an accumulation of DNA damage and decreased cell viability. Xenograft models further demonstrated that GW833972A treatment alone inhibited ARID1A-wt OCCC tumor growth. Together, our findings reveal an essential oncogenic role of BMAL2 and demonstrate that it is an appealing therapeutic target, especially for ARID1A-wt OCCC. Statement of significance: BMAL2 depletion, or degradation by a small molecule, led to DNA damage accumulation, decreased cell viability and reduced tumorigenesis of ARID1A-wildtype ovarian clear cell carcinoma, indicating that BMAL2 is an appealing therapeutic target for treating this malignant disease.
Open AccessBMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)
Ovarian clear cell carcinoma (OCCC) is highly chemo-resistant and has worse clinical outcome at advanced stages than other ovarian cancer subtypes. The most frequent (∼50%) alterations in OCCC are AT-rich interactive domain 1A gene (ARID1A) mutations which lead to ARID1A deficiency. However, OCCC that retains ARID1A function differs substantially from ARID1A mutated OCCC. Particularly, targeted therapies that sensitize ARID1A-deficient OCCC to DNA damage are largely ineffective against OCCC with wild-type (wt) ARID1A. Thus, it is important to identify druggable targets and develop targeted therapies specifically for ARID1A-wt OCCC. We identified BMAL2 as a critical OCCC oncogene that promotes tumorigenesis by preventing DNA damage from endogenous origins. BMAL2 depletion altered expression of genes in DNA damage repair pathways, including RAD51, a core enzyme of the homologous recombination (HR) pathway. This led to double-stranded break accumulation, decreased cell viability and reduced tumor growth. This dependence on BMAL2 to maintain DNA integrity and cell viability can be a new route to suppress ARID1A-wt OCCC. Consistent with this idea, we found that GW833972A, a cannabinoid receptor agonist, bound BMAL2 with high affinity and facilitated its degradation. This in turn reduced RAD51 expression, leading to an accumulation of DNA damage and decreased cell viability. Xenograft models further demonstrated that GW833972A treatment alone inhibited ARID1A-wt OCCC tumor growth. Together, our findings reveal an essential oncogenic role of BMAL2 and demonstrate that it is an appealing therapeutic target, especially for ARID1A-wt OCCC. Statement of significance: BMAL2 depletion, or degradation by a small molecule, led to DNA damage accumulation, decreased cell viability and reduced tumorigenesis of ARID1A-wildtype ovarian clear cell carcinoma, indicating that BMAL2 is an appealing therapeutic target for treating this malignant disease.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.